These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 36594390)

  • 1. [Research progress on the cardiorenal protection of non-steroid mineralocorticoid receptor antagonists in patients with chronic kidney disease].
    Liu WY; Yu SQ
    Sheng Li Xue Bao; 2022 Dec; 74(6):1023-1030. PubMed ID: 36594390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
    Pandey AK; Bhatt DL; Cosentino F; Marx N; Rotstein O; Pitt B; Pandey A; Butler J; Verma S
    Eur Heart J; 2022 Aug; 43(31):2931-2945. PubMed ID: 35713973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-steroidal mineralocorticoid receptor antagonists and cardiorenal outcomes in chronic kidney disease.
    Lo KB; Rangaswami J; Vaduganathan M
    Nephrol Dial Transplant; 2023 Mar; 38(4):845-854. PubMed ID: 36472546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.
    Agarwal R; Kolkhof P; Bakris G; Bauersachs J; Haller H; Wada T; Zannad F
    Eur Heart J; 2021 Jan; 42(2):152-161. PubMed ID: 33099609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiorenal Benefits of Finerenone in Different Races and Kidney Function in Patients with Chronic Kidney Disease.
    Li P; Cui Y; Xu X; Dong J; Liao L
    Cardiorenal Med; 2024; 14(1):227-234. PubMed ID: 38537621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of mineralocorticoid receptor antagonists in kidney diseases.
    Patel V; Joharapurkar A; Jain M
    Drug Dev Res; 2021 May; 82(3):341-363. PubMed ID: 33179798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Nonsteroidal Mineralocorticoid-Receptor-Antagonist Finerenone in Cardiorenal Medicine: A State-of-the-Art Review of the Literature.
    Georgianos PI; Agarwal R
    Am J Hypertens; 2023 Feb; 36(3):135-143. PubMed ID: 36331811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
    Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B
    Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists.
    Sueta D; Yamamoto E; Tsujita K
    Curr Hypertens Rep; 2020 Feb; 22(3):21. PubMed ID: 32114686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
    Kintscher U; Bakris GL; Kolkhof P
    Br J Pharmacol; 2022 Jul; 179(13):3220-3234. PubMed ID: 34811750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Time to Reconsider Mineralocorticoid Receptor Blocking Strategy: Arrival of Nonsteroidal Mineralocorticoid Receptor Blockers.
    Tezuka Y; Ito S
    Curr Hypertens Rep; 2022 Jul; 24(7):215-224. PubMed ID: 35488944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms.
    Epstein M; Kovesdy CP; Clase CM; Sood MM; Pecoits-Filho R
    Am J Kidney Dis; 2022 Nov; 80(5):658-666. PubMed ID: 36057467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of the Mineralocorticoid Receptor and Mineralocorticoid Receptor-Directed Therapies in Heart Failure.
    Young MJ; Kanki M; Karthigan N; Konstandopoulos P
    Endocrinology; 2021 Nov; 162(11):. PubMed ID: 34050730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes.
    Solis-Herrera C; Triplitt C
    Diabetes Obes Metab; 2024 Feb; 26(2):417-430. PubMed ID: 37885354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems.
    Kolkhof P; Lawatscheck R; Filippatos G; Bakris GL
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development.
    Kolkhof P; Bärfacker L
    J Endocrinol; 2017 Jul; 234(1):T125-T140. PubMed ID: 28634268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, on Cardiovascular Disease, Chronic Kidney Disease, and Blood Pressure.
    Ravid JD; Laffin LJ
    Curr Cardiol Rep; 2022 Oct; 24(10):1251-1259. PubMed ID: 35925515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease.
    Barrera-Chimal J; Gerarduzzi C; Rossignol P; Jaisser F
    Clin Sci (Lond); 2022 Jun; 136(12):1005-1017. PubMed ID: 35765983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease.
    Bramlage P; Swift SL; Thoenes M; Minguet J; Ferrero C; Schmieder RE
    Eur J Heart Fail; 2016 Jan; 18(1):28-37. PubMed ID: 26634965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
    Pitt B; Anker SD; Böhm M; Gheorghiade M; Køber L; Krum H; Maggioni AP; Ponikowski P; Voors AA; Zannad F; Nowack C; Kim SY; Pieper A; Kimmeskamp-Kirschbaum N; Filippatos G
    Eur J Heart Fail; 2015 Feb; 17(2):224-32. PubMed ID: 25678098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.